Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.66 |
| ▸ | FNTB | P49356 | 8/20 | 0.66 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765841 | 1.00 | FNTA (0.66) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL13093207 | 1.00 | FNTA (0.66) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL9510846 | 1.00 | FNTA (0.66) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051273 | 0.97 | FNTA (0.63) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051274 | 0.96 | FNTA (0.62) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30209468 | 0.96 | FNTA (0.62) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051169 | 0.94 | FNTA (0.63) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051757 | 0.94 | FNTA (0.59) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL6241495 | 0.92 | LTA4H (0.60) | FNTAFNTBPGGT1BLTA4HKMT2A | |
| SCHEMBL30051749 | 0.92 | FNTA (0.61) | FNTAFNTBPGGT1BLTA4HKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | claimed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | claimed |
| EP-4554623-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| EP-4554624-A1 | ANTIBODY-DRUG CONJUGATES | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| CN-119836305-A | Antibody-drug conjugates | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119836306-A | Antibody drug conjugates that bind CDCP1 and uses thereof | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| CN-118146294-A | Spirulina phycocyanin polypeptide and preparation method and application thereof | 山东福瑞达生物股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | claimed |
| WO-2024013723-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | claimed |
| WO-2024013724-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| JP-5032533-A | — | — | None | — | — | JP | disclosed |
| EP-0331404-A2 | Method for producing tropane alkaloid | SEITAIKINOU RIYOU KAGAKUHIN SHINSEIZOUGIJUTSU KENKYU KUMIAI (JP) | 1989-09-06 | — | — | EP | disclosed |
| EP-0033504-A2 | Pentapeptides of the encephaline type, process for their preparation and medicaments containing these | Richter Gedeon Vegyészeti Gyár R.T. (HU) | 1981-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | FNTA 388/4885FNTB 109/4885PGGT1B 178/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | FNTA 3505/4885FNTB 3093/4885PGGT1B 657/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | FNTA 3528/4885FNTB 2308/4885PGGT1B 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.